The High Cost of Medication: Copay Card Limits in Psoriatic Arthritis Treatment
Overview
Jayant Mishra, diagnosed with psoriatic arthritis, initially benefited from Amgen's copay assistance program for Otezla, which helped offset the drug's high cost. However, the copay card funds were exhausted quickly, leaving him responsible for substantial out-of-pocket expenses despite insurance coverage.
Background
Psoriatic arthritis is a chronic autoimmune condition causing joint pain and skin lesions. Otezla, a brand-name medication approved for this condition, has a high list price, often around $5,000 per month. Copay assistance programs by manufacturers aim to reduce patient costs but may not fully cover expenses due to insurer policies and deductibles. The interplay between insurers, pharmacy benefit managers, and drug manufacturers creates complexity in patient out-of-pocket costs.
Data Highlights
Month
Otezla Cost
Insurance Coverage
Copay Card Coverage
Patient Out-of-Pocket
First Month
$5,253.85
Partial
Full
$0
Second Month
$5,253.85
$308.34
Depleted
$441.02
Following Months
~$5,000 - $7,000
Partial
Partial
$400 - $550+
March Estimate
$6,995.36
Negotiated Price
Insufficient
$4,450 (estimated)
Key Findings
Otezla’s list price is approximately $5,000 for a 30-day supply, with negotiated insurer prices between $1,400 and $2,200.
Amgen’s copay card initially covered up to $9,450 annually but was depleted after two months of treatment.
Insurance coverage through UnitedHealthcare and its pharmacy benefit manager covered only a fraction of the drug’s full price, leading to significant patient responsibility.
Copay card payments do not count toward patients’ deductibles or out-of-pocket maximums, increasing financial burden.
Patients may resort to rationing medication doses when copay assistance runs out, risking symptom recurrence.
Legal actions by Amgen have delayed generic competition in the U.S., maintaining high brand-name drug prices.
Clinical Implications
Clinicians should counsel patients on the potential financial limitations of copay assistance programs and the possibility of unexpected out-of-pocket costs despite insurance coverage. Awareness of insurance plan details, including deductibles and pharmacy benefit manager negotiations, is essential to help patients manage medication adherence and financial planning. Exploring alternative therapies or assistance programs may be necessary when copay cards are exhausted.
Conclusion
While copay assistance programs can initially reduce patient costs for expensive medications like Otezla, their limited duration and insurer policies may leave patients facing substantial expenses. This case highlights the need for transparent communication and comprehensive financial planning in managing chronic autoimmune diseases.
References
KFF Health News 2025 -- The High Cost of Medication: How a Copay Card Assisted Until It No Longer Did
